NCT07059884 Distance-Based Exercise to Preserve Function and Prevent Disability
| NCT ID | NCT07059884 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alliance for Clinical Trials in Oncology |
| Condition | Hematopoietic and Lymphatic System Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 104 participants |
| Start Date | 2026-02-11 |
| Primary Completion | 2027-01-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.
Eligibility Criteria
Inclusion Criteria: * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed cancer * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent (for any malignancy) of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting for solid tumors are eligible. Patients receiving outpatient cytotoxic chemotherapy given for curative intent for hematologic malignancies, as well as patients receiving definitive chemoradiation for solid tumors, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible * REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years * RE